drugset / Trial / NCT05599802
Clinical Study of SARS-CoV-2 Variant mRNA Vaccine in Healthy Participants
Phase 1
Unknown
144 enrolled
AIM Vaccine Co., Ltd.
LiveRNA Therapeutics Inc. · collabNingbo Rongan Biological Pharmaceutical Co., Ltd. · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
An Open-Label, Phase 1 Clinical Study to Determine the Safety and Preliminary Immunogenicity of SARS-CoV-2 Variant mRNA Vaccine (LVRNA010)
Timeline
- Start
- 2023-02
- Primary completion
- 2023-05
- Completion
- 2024-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LVRNA010 | Messenger RNA (mRNA) | 50 ug | — |
| Subject | LVRNA010 | Messenger RNA (mRNA) | 100 ug | — |